Literature DB >> 21238824

Update on morphea: part II. Outcome measures and treatment.

Nicole Fett1, Victoria P Werth.   

Abstract

Morphea is a rare fibrosing disorder of the skin and underlying tissues. The underlying pathogenesis of morphea is not completely understood at this time, but ultimately results in an imbalance of collagen production and destruction. Evidence-based treatment options of morphea are limited secondary to the rarity of the disease, and the lack of universally used validated outcome measures. The most commonly used outcome measures are skin scores, computerized surface area measurement, durometer, cutometer, thermography, and ultrasound measurements. The Localized Scleroderma Cutaneous Assessment Tool is a promising recently validated skin scoring tool that allows differentiation between activity and damage, is sensitive to change, and requires no additional equipment. The most robust data in the treatment of morphea exists for methotrexate in combination with systemic steroids and ultraviolet A1. Copyright Â
© 2010 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21238824     DOI: 10.1016/j.jaad.2010.05.046

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  35 in total

Review 1.  Systemic sclerosis and localized scleroderma--current concepts and novel targets for therapy.

Authors:  Oliver Distler; Antonio Cozzio
Journal:  Semin Immunopathol       Date:  2015-11-17       Impact factor: 9.623

2.  Shiny white patches of the arms and forehead.

Authors:  Jason Emer; Dean David George; Sebastian Bernardo; Harleen Sidhu
Journal:  J Clin Aesthet Dermatol       Date:  2013-08

Review 3.  A Practical Approach to Juvenile Dermatomyositis and Juvenile Scleroderma.

Authors:  Liza J McCann; Clare E Pain
Journal:  Indian J Pediatr       Date:  2016-02       Impact factor: 1.967

4.  Update on management of connective tissue panniculitides.

Authors:  Inbal Braunstein; Victoria P Werth
Journal:  Dermatol Ther       Date:  2012 Mar-Apr       Impact factor: 2.851

Review 5.  Scleroderma mimics.

Authors:  Jennifer Nashel; Virginia Steen
Journal:  Curr Rheumatol Rep       Date:  2012-02       Impact factor: 4.592

Review 6.  Development of minimum standards of care for juvenile localized scleroderma.

Authors:  Tamás Constantin; Ivan Foeldvari; Clare E Pain; Annamária Pálinkás; Peter Höger; Monika Moll; Dana Nemkova; Lisa Weibel; Melinda Laczkovszki; Philip Clements; Kathryn S Torok
Journal:  Eur J Pediatr       Date:  2018-05-04       Impact factor: 3.183

7.  Treatment of morphea with hydroxychloroquine: A retrospective review of 84 patients at Mayo Clinic, 1996-2013.

Authors:  Anagha Bangalore Kumar; Elizabeth K Blixt; Lisa A Drage; Rokea A El-Azhary; David A Wetter
Journal:  J Am Acad Dermatol       Date:  2019-01-29       Impact factor: 11.527

Review 8.  Corticosteroids in Myositis and Scleroderma.

Authors:  Anna Postolova; Jennifer K Chen; Lorinda Chung
Journal:  Rheum Dis Clin North Am       Date:  2015-10-26       Impact factor: 2.670

Review 9.  Practice and Educational Gaps in Lupus, Dermatomyositis, and Morphea.

Authors:  Nicole M Fett; David Fiorentino; Victoria P Werth
Journal:  Dermatol Clin       Date:  2016-07       Impact factor: 3.478

10.  Histopathological changes in morphea and their clinical correlates: Results from the Morphea in Adults and Children Cohort V.

Authors:  Daniel Walker; Joseph S Susa; Sharif Currimbhoy; Heidi Jacobe
Journal:  J Am Acad Dermatol       Date:  2017-03-09       Impact factor: 11.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.